PharmTech Weekly Roundup—April 17, 2026

Welcome to PharmTech’s Weekly Roundup. I’m Susan Haigney, Lead Editor of PharmTech.

This week on PharmTech.com, experts discussed digital transformation through AI and real-time monitoring, strategic collaborations to solve complex logistical hurdles, and the ongoing challenge of navigating an increasingly unpredictable regulatory landscape.

In news, Regeneron and Telix entered a $2.1 billion collaboration that pairs Regeneron's antibody discovery platforms and clinical oncology portfolio with Telix's radiopharmaceutical development infrastructure, manufacturing capabilities, and global supply chain.

In upcoming conference coverage, look for PharmTech editors at INTERPHEX next week, where we will be interviewing industry experts on a variety of topics. In other conference news, CPHI Americas announced their 2026 agenda, which centers on the critical intersections of shifting regulatory policies, AI integration in drug discovery, and strengthening global supply chain resilience. And upcoming exhibits at Interpack 2026 will showcase modular, digitally transparent, and sustainable packaging solutions designed to handle increasing formulation and regulatory complexity.

In a preview of his presentation at the upcoming Excipient World in May, Dave Schoneker of Black Diamond Regulatory Consulting and a member of PharmTech’s editorial advisory board talks about the pathway for developing new excipients. The adoption of novel excipients remains slow due to intensive safety requirements and industry reluctance, yet they are increasingly vital for the successful commercialization of complex large molecules. Dave will also be providing insight on the workshop he is leading at the event.

Be sure to check out PharmTech’s conference page for more.

European Frontrunners Columnist, Cheryl Barton, focuses on European biotechs leveraging AI, multi-omics, and cell therapies to address the root causes of cardiovascular disease, driving a market projected to reach $215 billion by 2034.

In an interview with PharmTech, Andrew Chang and Steven Falcone of Novo Nordisk, provide insight into how Novo Nordisk utilizes the FDA-EU mutual recognition framework alongside a proactive internal signal-monitoring process to maintain systemic global GMP compliance across its manufacturing network and how the company is advancing a vision for a "globally interconnected digital network" that employs real-time sensor data and automated visual inspections to modernize quality management.

Whether through the adoption of real-time digital monitoring or the formation of specialized manufacturing alliances, the industry is clearly moving toward a more precision-oriented model.

Stay informed as these technologies and policies continue to reshape workflows.

Visit PharmTech.com to read more about these and other industry trends.